My Bookmarks
As you browse, bookmark any page and then find it here for easy reference.
You have 0 bookmarks.
Reviews the future of mood-disorder research, covering identification of new therapeutic targets, preclinical models, and medicinal chemistry opportunities, and increasing understanding of genetic influences. Essential reading for everyone involved in psychopharmacology development, and mental health clinicians seeking a preview of discoveries soon to influence their practice.
As you browse, bookmark any page and then find it here for easy reference.
You have 0 bookmarks.
As the World Health Organization estimates that depression will become the second leading cause of death by the year 2020 – due primarily to complications arising from stress and the cardiovascular system – the need to develop novel and more effective treatment strategies for patients suffering with mood disorders has never been more paramount. Current treatment options for depressed patients include a variety of molecules designed to exclusively elevate central nervous system levels of monoamines such as serotonin (5-HT). These classes include the monoamine oxidase inhibitors and tricyclics and are exemplified by the selective serotonin reuptake inhibitors (SSRIs) and the dual serotonin/norepinephrine reuptake inhibitors (SNRIs). While these medicines are moderately effective in some patient populations, there are still considerable limitations associated with all commercially available antidepressants. These drawbacks include, but are not limited to, delayed onset of efficacy, treatment resistance in many patients, and deleterious side effects such as emesis and sexual dysfunction. The focus of this book is to review the current landscape and state of the field for depression research with an eye towards shedding light on where the future of mood disorders research is headed in terms of novel therapeutic targets, preclinical model development, exploring depression endophenotypes, and medicinal chemistry strategies. Undoubtedly all of these disciplines, as well as others including genetics and translational medicine approaches, will need to successfully collaborate to help build a better understanding of disease etiology, patient stratification, and treatment. As depression research has evolved over the past 50 years, the next decade will be instrumental in facilitating a move beyond our current understanding and pharmacological treatment options, and strive to discover and develop more personalized and effective treatment options for the millions of patients suffering from chronic and debilitating mood disorders.
Chad E. Beyer, PhD, MBAChapter 1 |
Chapter 5 |
---|---|
Current depression landscape: a state of the field today | Defining depression endophenotypes |
Chapter 2 |
Chapter 6 |
Novel therapeutic targets for treating affective disorders | Genetic and genomic studies of major depressive disorder |
Chapter 3 |
Chapter 7 |
Developing novel animal models of depression | Medicinal chemistry challenges in the design of next generation antidepressants |
Chapter 4 |
Chapter 8 |
Translational research in mood disorders: using imaging technologies in biomarker research | Application of pharmacogenomics and personalized medicine for the care of depression |
Chapter 6 Genetic and genomic studies of major depressive disorder
Family studies indicate that major depressive disorder runs in families, although family members’ risk for other psychiatric disorders may also be increased. Twin and adoption studies suggest that about one-third of the liability for MDD is inherited. Studies investigating individual candidate genes have failed to implicate any single gene in MDD risk. Emerging evidence from genome-wide association studies may identify novel risk genes, although any individual genetic variation appears likely to have only modest effect. Whether focusing on clinical subtypes of MDD, or relying on imaging or other biomarkers rather than clinical features, will expedite the process of gene discovery remains to be determined.